BBIO
BridgeBio Pharma·NASDAQ
--
--(--)
--
--(--)
4.55 / 10
Netural
Sentiment score 4.55 (neutral) but fund‑flow rating is good (7.88), with positive inflows across all block sizes. Analysts unanimously rate Buy (3/3), yet historical win rates are low. Mixed picture: strong buying pressure but uncertain analyst performance.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-10
InstitutionJP Morgan
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of BBIO?
- BBIO holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.55/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
